Tuesday, 19 Mar 2019

You are here

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.

Hilliquin and colleagues undertook a systematic literature review and meta-analysis to assess if there are randomised controlled trials of disease-modifying antirheumatic drugs (DMARDs) or glucocorticoids used in at risk individuals - those with genetic and/or environmental risk factors and/or systemic autoimmunity associated with RA, without clinical synovitis/arthritis. 

They identified 10 trials that included 1156 patients, with mean symptom duration 16.2±12.6 weeks.

In those with  arthralgia, and without arthritis (people at risk of RA), two available studies failed to show significant reduction in RA occurrence at week 52 or more (pooled OR 0.74, 95% CI 0.37 to 1.49).

For people with undifferentiated arthritis, seven studies revealed significant risk reduction with OR 0.73(95% CI 0.56 to 0.97) in the development of RA.

This metanalysis shows that early therapeutic intervention may significantly reduce the risk of RA onset but only those with undifferentiated arthritis.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Multiple Delays in Referral of New RA Patients

A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.

Does Smoking Cessation Reduce RA Risk?

Individuals who quit smoking and maintained their nonsmoking status over a long duration of time had a decreased risk of developing seropositive rheumatoid arthritis (RA), an analysis of two large prospective cohorts found. 

Remission Unlikely in RA

Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."

No Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis

A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.